Virios Therapeutics, LLC

VIRI50

Penny Stock

$0.15arrow_drop_up16.89%$0.02

Penny Stock

VIRI50

$0.15

arrow_drop_up16.89%$0.02

Penny Stock

Performance History

Key Stats
Open	$0.20
Prev. Close	$0.13
EPS	-5.75
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-
Market Cap	$206.50K
PE Ratio	-

	LOW	HIGH
Day Range	0.14	0.24
52 Week Range	0.13	1.04

Ratios

Revenue	-



EBITDA Margin %	-

EPS	-5.75

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About Virios Therapeutics, LLC (VIRI)

Virios Therapeutics, LLC (VIRI) is a biopharmaceutical company focused on the development and commercialization of novel therapies for the treatment of viral diseases. The company's pipeline consists of innovative antiviral drugs targeting a range of viral infections, including respiratory viruses, hepatitis viruses, and herpes viruses. With a strong emphasis on research and development, Virios Therapeutics is dedicated to addressing unmet medical needs and improving the lives of patients worldwide.

The stock price history of Virios Therapeutics, LLC (VIRI) reflects the company's growth and potential. Over the past year, the stock has demonstrated significant volatility, but overall, it has shown a positive trend. Investors who have been following the company closely have witnessed the potential of its drug candidates and the positive response they have received from the market. As a result, the stock price has experienced upward momentum, reflecting the growing confidence in Virios Therapeutics' future prospects.

Websitecall_made

Sector: Healthcare
Industry: Biotechnology
CEO: Mr. Gregory Duncan
Headquarters: Alpharetta
Employees: 4
Exchange: NASDAQ

add Virios Therapeutics, LLC to watchlist

Keep an eye on Virios Therapeutics, LLC

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is the market capitalization of Virios Therapeutics, LLC (VIRI)?

Virios Therapeutics, LLC (VIRI) has a market capitalization of $206.5K. The average daily trading volume is 0.18, indicating the stock's liquidity and investor engagement.

help

What is Virios Therapeutics, LLC's (VIRI) price per share?

The current price per share for Virios Therapeutics, LLC (VIRI) is $0.15. The stock has seen a price change of $0.02 recently, indicating a 16.9% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for Virios Therapeutics, LLC (VIRI)?

For Virios Therapeutics, LLC (VIRI), the 52-week high is $1.04, which is 570.97% from the current price. The 52-week low is $0.13, the current price is 17.42% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is Virios Therapeutics, LLC (VIRI) a growth stock?

Virios Therapeutics, LLC (VIRI) has shown an average price growth of -6.65% over the past three years. It has received a score of 30 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Virios Therapeutics, LLC as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is Virios Therapeutics, LLC (VIRI) stock price performance year to date (YTD)?

As of the latest data, Virios Therapeutics, LLC (VIRI) has a year-to-date price change of -98.94%. Over the last three months, the change has been -96.72%. Over the past six months, the figure is -98.39%.

help

Is Virios Therapeutics, LLC (VIRI) a profitable company?

Virios Therapeutics, LLC (VIRI) has a net income of -$5.3M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 0% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. Operating income is noted at -$5.45M. Furthermore, the EBITDA is $0.